Julia K. Gittler

https://assets.montefioreeinstein.org/profiles/images/physphoto/Gittler_Julia_MD_420x504.jpg

First Name

Julia

Last Name

Gittler

NPI

1427492081

Faculty ID

16099

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="mso-pagination: widow-orphan;">Julia K. Gittler, MD, is an attending physician and Assistant Professor at Montefiore-Einstein. Dr. Gittler&rsquo;s clinical areas of focus include all areas of pediatric dermatology, including eczema, vascular and other birthmarks, acne, genetic skin disorders and other pediatric dermatologic conditions.</p>
<p class="MsoNormal">Dr. Gittler earned her Bachelor of Arts at the University of Pennsylvania College of Arts and Sciences in 2008 and graduated summa cum laude. From 2008 to 2013, she attended the Albert Einstein College of Medicine, receiving her Doctor of Medicine and earning distinction in dermatology research through a research fellowship at the Rockefeller University. Her training also includes completion of a yearlong pediatrics internship at Cohen Children&rsquo;s Medical Center in 2014, a three-year dermatology residency at New York University in 2017 and a yearlong pediatric dermatology fellowship at Columbia University in 2018.</p>
<p class="MsoNormal" style="mso-pagination: widow-orphan;">Following her clinical interests, Dr. Gittler&rsquo;s research focus is on pediatric dermatology. Her work has been published in many peer-reviewed journals. She has also shared her research through poster presentations and lectures at regional and national conferences.</p>
<p class="MsoNormal" style="mso-pagination: widow-orphan;">Dr. Gittler is certified in pediatric dermatology by the American Board of Dermatology. She is a member of the American Academy of Dermatology and the Society of Pediatric Dermatology.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

102886

Is Open Scheduling

On

Benedict C. Wu

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/41dd1920-3372-11ec-868d-89cf3c4ab01c.jpg

First Name

Benedict

Last Name

Wu

NPI

1730538596

Faculty ID

17053

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Benedict (Benny) Wu, DO, PhD, is the Director of Inpatient Dermatology and Assistant Professor at Montefiore-Einstein. Dr. Wu&rsquo;s clinical interests extend to inpatient and complex medical dermatology areas, including connective tissue disorders, autoimmune bullous disorders, immunodermatology, cutaneous presentation of systemic conditions, and cutaneous lymphomas.</p>
<p>After earning his Bachelor of Science in biological sciences from the University of California, Irvine, Dr. Wu attended the University of Medicine and Dentistry of New Jersey, earning his Master of Biomedical Sciences. He later attended Rowan University, earning his Doctor of Philosophy in Cell and Molecular Biology in 2014 and his Doctor of Osteopathic Medicine in 2016. His postdoctoral training began with an internship in internal medicine at Drexel University College of Medicine, followed by a clinical research fellowship at Northwestern University. In 2021, he completed his Dermatology residency at Broward Health in Fort Lauderdale, Florida.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">&nbsp;Dr. Wu&rsquo;s clinical interests extend to inpatient and complex medical dermatology areas, including connective tissue disorders, autoimmune bullous disorders, immunodermatology, cutaneous presentation of systemic conditions, and cutaneous lymphomas.</span>

Research Focus

<span style="color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">Dr. Wu&rsquo;s research investigates several questions. His research focus spans from his work in the clinic to the basic sciences. For example, does physical and/or emotional stress significantly exacerbate complex medical dermatoses? In the future, he hopes to examine neutrophil dysfunction at the cellular and molecular level from tissue and blood samples from neutrophil-predominant dermatoses.</span>

Elsevier Profile

Selected Publications

<p><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif; color: #212121;">Hopkins ZH, Wu BC, Nousari CH. Rituximab versus Mycophenolate Mofetil in Pemphigus Vulgaris.&nbsp;</span><em><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif; color: #212121;">N Engl J Med</span></em><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif; color: #212121;">. 2021;385(11):1055-1056. doi:10.1056/NEJMc2111763</span></p>
<p><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif; color: #212121;">Nousari Y, Wu BC, Tausk F. From the Caravels to the Wards: Scurvy and Schizophrenia [published online ahead of print, 2021 Jun 8].&nbsp;<em>J Acad Consult Liaison Psychiatry</em>. 2021;S2667-2960(21)00097-5. doi:10.1016/j.jaclp.2021.05.006</span></p>
<p><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif;">Nousari Y, Wu BC, Valenzuela G. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome [published online ahead of print, 2021 Apr 29].&nbsp;<span class="em" style="border: none; vertical-align: baseline;"><em><span style="border: none;"><span style="border: none;">Clin Exp Dermatol</span></span></em></span>. 2021;10.1111/ced.14712. doi:10.1111/ced.14712</span></p>
<p><span style="font-size: 11pt; font-family: 'Century Gothic', sans-serif;">Erickson, T. R., Murphrey, M. B., Abu-Zayed, H., Wu, B., Ibler, E., Rangel, S. M., &amp; Paller, A. S. (2020). Transepidermal water loss in the orphan forms of ichthyosis.&nbsp;<span class="em" style="border: none; vertical-align: baseline;"><em><span style="border: none;"><span style="border: none;">Pediatric dermatology</span></span></em></span>,&nbsp;<span class="em" style="border: none; vertical-align: baseline;"><em><span style="border: none;"><span style="border: none;">37</span></span></em></span>(4), 771&ndash;773. https://doi.org/10.1111/pde.14221</span></p&gt;

EMR ID

159114

Biography

<p style="padding-top:0px;color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">Benedict (Benny) Wu, DO, PhD, is the Director of Inpatient Dermatology and Assistant Professor at Montefiore-Einstein. Dr. Wu&rsquo;s clinical interests extend to inpatient and complex medical dermatology areas, including connective tissue disorders, autoimmune bullous disorders, immunodermatology, cutaneous presentation of systemic conditions, and cutaneous lymphomas.</p><p style="padding-top:0px;color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">After earning his Bachelor of Science in biological sciences from the University of California, Irvine, in 2006, Dr. Wu attended the University of Medicine and Dentistry of New Jersey, earning his Master of Biomedical Sciences in 2007. He later attended Rowan University, earning his Doctor of Philosophy in Cell and Molecular Biology in 2014 and his Doctor of Osteopathic Medicine in 2016. His postdoctoral training began with an internship in internal medicine at Drexel University College of Medicine in 2017, followed by a clinical research fellowship at Northwestern University in 2018. In 2021, he completed a three-year dermatology residency at Broward Health.</p><p style="padding-top:0px;color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">Dr. Wu&rsquo;s research investigates several questions. His research focus spans from his work in the clinic to the basic sciences. For example, does physical and/or emotional stress significantly exacerbate complex medical dermatoses? In the future, he hopes to examine neutrophil dysfunction at the cellular and molecular level from tissue and blood samples from neutrophil-predominant dermatoses. He has shared his research in many oral and poster presentations, as well as in peer-reviewed publications.</p><p style="padding-top:0px;color:#525458;font-family:Arial, Helvetica, sans-serif;background-color:#ffffff;">Dr. Wu is a member of several professional societies, including the American Academy of Dermatology, the Medical Dermatology Society, the Society for Dermatological Hospitalists, and the Society for Investigative Dermatology.</p>

Is Open Scheduling

On

Daniel A. Weiser

https://assets.montefioreeinstein.org/profiles/images/Weiser_Daniel_MD_2x.jpg

First Name

Daniel

Last Name

Weiser

NPI

1225239700

Faculty ID

13846

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>.&nbsp; We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>.&nbsp; With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.&nbsp;</p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based &ldquo;liquid&rdquo; biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA &ldquo;aging&rdquo; signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children&rsquo;s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. &ndash; Stony Brook University, NY</li>
<li>Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency &ndash; Children&rsquo;s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship &ndash; The Children&rsquo;s Hospital of Philadelphia, PA</li>
</ul>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.&nbsp;

Research Focus

Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.

Elsevier Profile

EMR ID

5755

Biography

<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children&rsquo;s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children&rsquo;s Hospital of Philadelphia. </p><p>Dr. Weiser&rsquo;s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser&rsquo;s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children&rsquo;s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>

Is Open Scheduling

Off

Ellen D. Teplitz

https://assets.montefioreeinstein.org/profiles/images/2882-teplitz.jpg

First Name

Ellen

Last Name

Teplitz

NPI

1174683742

Faculty ID

2882

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

3602

Is Open Scheduling

Off

Alejandra I. Sacasa

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/def64050-0f08-11ef-8dfd-d5d86707fe54.jpg

First Name

Alejandra

Last Name

Sacasa

NPI

1730542796

Faculty ID

17644

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

113616

Is Open Scheduling

Off

Orna Rosen

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/52f35570-35f2-11ed-8123-8ffce84a9f6a.jpg

First Name

Orna

Last Name

Rosen

NPI

1205912151

Faculty ID

1126

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3910

Is Open Scheduling

Off

Lisa Morrow

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Lisa

Last Name

Morrow

NPI

1174849640

Faculty ID

15916

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Clinical Type

Nurse Practitioner

EMR ID

6363

Is Open Scheduling

Off

Beth N. McLellan

https://assets.montefioreeinstein.org/profiles/images/physphoto/McLellan_Beth_MD_LC_420x504.jpg

First Name

Beth

Last Name

McLellan

NPI

1356512412

Faculty ID

14084

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Beth McLellan graduated with honors from Northwestern University and attended medical school at Wayne State University where she graduated with Alpha Omega Alpha honors. She completed an internship in Internal Medicine at Loyola University Health System and her Dermatology residency at Henry Ford Health System in Detroit where she also served as Chief Resident. She currently is a Professor in the Department of Medicine (Dermatology) and has served as Chief of the Division of Dermatology since 2020.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. McLellan specializes in complex medical Dermatology and has a special interest in Supportive Oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair, and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis as well as successful use of bacterial decolonization for prevention of radiation dermatitis. She has published numerous articles and textbook chapters related to Supportive Oncodermatology and is regularly invited to speak at Dermatology and Oncology conferences for physicians and patients including the annual meeting of the American Academy of Dermatology, ASCO, and Gilda's Club.</span></p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Playing an active role in the Dermatology Residency, Dr. McLellan is the director of resident research and regularly lectures residents and medical students. She has served as a mentor to many residents and students and directs a year-long Oncodermatology research fellowship for medical students taking a year off for research.&nbsp; Interested medical students can learn more about the fellowship here: https://www.einsteinmed.edu/departments/medicine/divisions/dermatology/…;
<div>&nbsp;</div>
<div>&nbsp;</div>
<div>&nbsp;</div>
<p>&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. McLellan specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.

Research Focus

Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis

Elsevier Profile

Selected Publications

<p><a href="https://www.ncbi.nlm.nih.gov/sites/myncbi/1-KCbcoWaApUyh/bibliography/5…;

EMR ID

5777

Biography

<p>Beth N. McLellan, MD, is Chief, Dermatology, Director, Supportive Oncodermatology and Professor, Dermatology at Montefiore Einstein. She specializes in complex medical dermatology and has a special interest in supportive oncodermatology - the treatment of dermatologic diseases in cancer patients. She works closely with oncologists to prevent and treat skin, hair and nail-related side effects due to cancer therapies and is committed to improving the lives of cancer patients.</p><p>After earning her Doctor of Medicine at Wayne State University, Dr. McLellan completed an internship in internal medicine at Loyola University Health System and her dermatology residency at Henry Ford Health System where she also served as chief resident and initiated a supportive oncodermatology clinic. Dr. McLellan received additional oncodermatology training at Memorial Sloan Kettering Cancer Center and at the Institut Gustave Roussy in Paris, France.</p><p>Dr. McLellan leads research examining radiation dermatitis and was the first to describe baseline bacterial colonization as a risk factor for severe radiation dermatitis. Playing an active role in the Montefiore Einstein Dermatology Residency, Dr. McLellan is the Director of Resident Research and regularly lectures residents and medical students at both dermatology and oncology meetings. She has served as a mentor to many residents and students and directs a year long oncodermatology research fellowship for medical students taking a year off for research. Dr. McLellan has published numerous articles and textbook chapters related to supportive oncodermatology and is regularly invited to speak at dermatology and oncology conferences for physicians and patients, including the annual meeting of the American Academy of Dermatology, American Society of Clinical Oncology and Gilda's Club.</p><p>As part of her commitment to treating the whole patient, Dr. McLellan founded the New York Vitiligo Support Group. She has received awards from the Dermatology Foundation.</p>

Is Open Scheduling

On

Ranon E. Mann

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c72bf490-4533-11ef-aaf9-f7685684de7b.jpg

First Name

Ranon

Last Name

Mann

NPI

1730279530

Faculty ID

5362

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

As Program Director my clinical focus is patient care and resident education. My interests surround<br />complex medical dermatology.

Research Focus

Research focus on skin disorders affecting patients who are HIV positive.

Elsevier Profile

EMR ID

4051

Is Open Scheduling

On

Tobi B. Klar

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/bbff55b0-470e-11ec-a9e7-9bd94149ce2f.jpg

First Name

Tobi

Last Name

Klar

NPI

1609934264

Faculty ID

5357

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="font-family:Calibri, sans-serif;font-size:16px;">Dr. Klar&rsquo;s clinical expertise includes general dermatological procedures, as well as more complex procedures such as the treatment of psoriasis and inflammatory dermatoses with phototherapy, topical therapy and biologic therapy.</span>

Research Focus

<span style="font-family:Calibri, sans-serif;font-size:16px;">Dr. Klar&rsquo;s research interests are in treatment options for acne, psoriasis and eczema.</span>

EMR ID

46138

Biography

<p><span style="font-size:12.0pt;font-family:'Calibri',sans-serif;">Tobi Klar, MD, is an attending physician and Assistant Professor at Montefiore-Einstein. Dr. Klar&rsquo;s clinical expertise includes general dermatological procedures, as well as more complex procedures such as the treatment of psoriasis and inflammatory dermatoses with phototherapy, topical therapy and biologic therapy. Dr. Klar also treats cancers of the skin including melanoma, basal cell carcinoma and squamous cell carcinoma.<span>&nbsp; </span>She has advanced training and extensive experience treating adults and children for general dermatological conditions, including rashes, acne, rosacea and eczema. She also performs skin cancer screenings and treats premalignant and malignant conditions.</span></p> <p><span style="font-size:12.0pt;font-family:'Calibri',sans-serif;">After earning her Doctor of Medicine at the State University of New York Downstate in 1981, Dr. Klar continued at the institution for her postdoctoral training, completing her Internal Medicine Internship in 1982, her Internal Medicine Residency in 1983 and her Dermatology Residency in 1986.</span></p> <p><span style="font-size:12.0pt;font-family:'Calibri',sans-serif;">Dr. Klar&rsquo;s research interests are in treatment options for acne, psoriasis and eczema. </span></p> <p><span style="font-size:12.0pt;font-family:'Calibri',sans-serif;">Dr. Klar is board certified and is a member of several professional associations including the Society for Clinical Vascular Surgery, the Society of Vascular Ultrasound and the Peripheral Vascular Surgery Society.</span></p>

Is Open Scheduling

On